Jesse C. Nussbaum

Jesse C. Nussbaum

Auto-generated profile, based on publicly available information

Jesse C. Nussbaum

Merck & Co., Inc. Rahway New Jersey USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Vaccine
Verified
Journal Article
Closed access
JNJesse Nussbaum
Jesse Nussbaum
XCXin Cao
Xin Cao
RRRadha A. Railkar
Radha A. Railkar
JSJeffrey R. Sachs
Jeffrey R. Sachs
DSDaniel S. Spellman
Daniel S. Spellman
AEAmy S. Espeseth
Amy S. Espeseth

25 June 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GWGeoffrey A. Walford
Geoffrey A. Walford
ABAn Bautmans
An Bautmans
CCCarol Cannon
Carol Cannon
KDKelly E. Duncan
Kelly E. Duncan
KDKathleen Deschamps
Kathleen Deschamps
SSS. Aubrey Stoch
S. Aubrey Stoch

1 February 2022 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
JNJesse C. Nussbaum
Jesse C. Nussbaum
AHAzher Hussain
Azher Hussain
BMBennett Ma
Bennett Ma
KMK. Chris Min
K. Chris Min
QCQing Chen
Qing Chen
SSS. Aubrey Stoch
S. Aubrey Stoch
Gefapixant (MK‐7264) is a first‐in‐class, selective antagonist of the P2X3 purinergic receptor currently being investigated as a therapeutic agent for the treatment of refractory or unexplained chronic cough. In non‐clinical studies, gefapixant was eliminated primarily by renal excretion of the parent drug. The objective of this study was to assess the disposition of gefapixant in humans. The absorption, metabolism, and excretion profiles of gefapixant were assessed after oral administration of a single dose of [14C]gefapixant to six healthy adult males. Following a single‐oral [14C]gefapixant dose to healthy adult males, the mass balance was achieved, with 98.9% of the administered radioactivity recovered in urine and feces. Elimination of gefapixant occurred primarily via renal excretion of the intact drug (64%); metabolism was a minor pathway of elimination of gefapixant (12% and 2% recovered in urine and feces, respectively). Single‐dose administration of [14C]gefapixant 50 mg was generally well tolerated in healthy adult males. The fraction of the anticipated therapeutic oral dose of gefapixant absorbed is estimated to be at least 78%. Gefapixant is expected to be the major circulating drug‐related material in plasma, and the majority of the dosed drug will be excreted unchanged in urine.

19 June 2021 in Clinical Pharmacology in Drug Development
Verified
Journal Article
Closed access
PDF file
JNJesse C. Nussbaum
Jesse C. Nussbaum
AHAzher Hussain
Azher Hussain
BMBennett Ma
Bennett Ma
KMK. Chris Min
K. Chris Min
RERaymond Evers
Raymond Evers
MIMarian Iwamoto
Marian Iwamoto

23 April 2024 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
JNJesse C. Nussbaum
Jesse C. Nussbaum
AHAzher Hussain
Azher Hussain
PBPeter Butera
Peter Butera
AFAnthony P. Ford
Anthony P. Ford
MKMichael M. Kitt
Michael M. Kitt
MIMarian Iwamoto
Marian Iwamoto
Gefapixant (MK‐7264, RO4926219, AF‐219) is a first‐in‐class P2X3 antagonists being developed to treat refractory or unexplained chronic cough. The initial single‐ and multiple‐dose safety, tolerability, and pharmacokinetics of gefapixant at doses ranging from 7.5 to 1800 mg were assessed in four clinical trials. Following single‐dose administration of 10‐450 mg, the pharmacokinetic (PK) profile of gefapixant in plasma and urine demonstrated low inter‐subject variability and a dose‐proportional exposure. Following administration of multiple doses twice daily, the plasma exposures were dose‐proportional at doses ranging from 7.5 to 50 mg and less than dose‐proportional at doses ranging from 100 to 1800 mg. The time to mean peak drug concentration ranged from 2 to 3 h post‐dose, and steady state was achieved by 7 days after dosing, with an accumulation ratio of approximately 2, comparing data from day 1 to steady state. The mean apparent terminal half‐life ranged from 8.2 to 9.6 h. Gefapixant was primarily excreted unmodified in urine. Gefapixant was well tolerated following single‐dose administration up to 1800 mg and multiple doses up to 1800 mg twice daily; there were no serious adverse events (AEs) reported. The most common AE reported was dysgeusia. The PK profile supports a twice‐daily dosing regimen.

7 July 2022 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
JNJesse C. Nussbaum
Jesse C. Nussbaum
AHAzher Hussain
Azher Hussain
KMK. Chris Min
K. Chris Min
TMThomas C. Marbury
Thomas C. Marbury
KLKenneth Lasseter
Kenneth Lasseter
MIMarian Iwamoto
Marian Iwamoto